시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 엠파글리플로진, 다파글리플로진, 카나글리플로진 시장 보고서(2025년)
Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2025
상품코드 : 1825725
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,527,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,434,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,341,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

엠파글리플로진, 다파글리플로진, 카나글리플로진 시장 규모는 향후 몇 년 동안 안정적으로 성장할 것으로 예상됩니다. 2029년에는 연평균 성장률(CAGR) 2.4%로 108억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장 배경에는 경구용 당뇨병 치료제 수요 증가, 당뇨병 연구 및 개발 투자 증가, 의료비 지출 증가, 예비 당뇨병 환자에 대한 인식 및 진단 증가, 병용요법에 대한 관심 증가 등이 있습니다. 예측 기간의 주요 동향으로는 기술 발전, 병용요법, 원격의료, 건강 데이터 분석, 환자 데이터 보안 등이 있습니다.

향후 5년간 2.4%의 성장률 전망은 지난번 예측보다 0.3% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 인도와 독일에서 수입되는 SGLT2 억제제의 비용을 상승시키고, 환자의 접근성을 제한하며, 내분비내과 치료비용을 상승시킬 수 있기 때문에 미국의 당뇨병 관리에 혼란을 초래할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

당뇨병 유병률의 증가는 엠파글리플로진, 다파글리플로진, 카나글리플로진 시장의 확대를 견인할 것으로 예상됩니다. 당뇨병은 인슐린 분비 부족 또는 인슐린을 효과적으로 사용할 수 없는 체질로 인한 고혈당을 특징으로 하는 만성질환입니다. 당뇨병 환자의 증가는 좌식 생활습관, 식습관 장애, 유전적 요인, 도시화, 고령화, 의료 서비스 접근성 제한, 전 세계 비만율 증가 등 다양한 요인에 기인합니다. 엠파글리플로진, 다파글리플로진, 카나글리플로진은 신장의 나트륨-포도당 공수송체-2(SGLT2)를 억제하여 혈당을 낮추고 소변을 통한 포도당 배설을 촉진하여 당뇨병을 관리하는 데 사용됩니다. 예를 들어, 2024년 6월 국민보건서비스(NHS)는 40세 미만 당뇨병 환자가 급증하여 2022년 17만 3,166명에서 2023년 21만 6,440명으로 증가했다고 보고했습니다. 이러한 급격한 증가는 젊은 층의 우려할 만한 추세를 잘 보여주고 있습니다. 그 결과, 당뇨병 유병률의 증가는 엠파글리플로진, 다파글리플로진, 카나글리플로진, 카나글리플로진의 시장 성장에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Empagliflozin, dapagliflozin, and canagliflozin are medications known as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, primarily prescribed for managing type 2 diabetes mellitus. These oral medications are part of a comprehensive diabetes treatment plan that also involves diet, exercise, and potentially other medications.

The specific types of these SGLT-2 inhibitors include empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is used mainly to reduce blood sugar levels in adults with type 2 diabetes by aiding the kidneys in expelling glucose through urine. These medications are available in various applications, including application I, application II, application III, and application IV, and can be purchased through hospitals and pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports from The Business Research Company that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with an empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends, and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.64 billion in 2024 to $9.84 billion in 2025 at a compound annual growth rate (CAGR) of 2.1%. The growth in the historic period can be attributed to the increase in the prevalence of type 2 diabetes globally, increased awareness about the benefits of SGLT2 inhibitors, growth in the elderly population, growth in the prevalence of obesity, and increase in focus on personalized medicine.

The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $10.82 billion in 2029 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to increasing demand for oral diabetes medications, increasing investments in diabetes research and drug development, increasing healthcare expenditure, rising awareness and diagnosis of pre-diabetes conditions, and increasing focus on combination therapies. Major trends in the forecast period include technological advancements, combination therapies, telehealth, health data analytics, and patient data security.

The forecast of 2.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. diabetes management by increasing costs for SGLT2 inhibitors imported from India and Germany, potentially limiting patient access and raising endocrinology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of diabetes is expected to drive the expansion of the empagliflozin, dapagliflozin, and canagliflozin market. Diabetes is a chronic health condition characterized by high blood sugar levels due to insufficient insulin production or the body's inability to use insulin effectively. The rise in diabetes cases can be attributed to various factors, including sedentary lifestyles, poor dietary choices, genetic factors, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Empagliflozin, dapagliflozin, and canagliflozin are used to manage diabetes by lowering blood sugar levels through the inhibition of sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urine. For example, in June 2024, the National Health Service (NHS) reported a sharp increase in diabetes cases among individuals under 40, rising from 173,166 in 2022 to 216,440 in 2023. This rapid rise underscores a concerning trend in the younger population. As a result, the growing prevalence of diabetes is fueling the market growth for empagliflozin, dapagliflozin, and canagliflozin.

Key players in the empagliflozin, dapagliflozin, and canagliflozin markets are concentrating on creating innovative products, such as treatments for pediatric type-2 diabetes, to cater to a wider patient base and enhance their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar through lifestyle modifications, medications, and occasionally insulin therapy specifically designed for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 and older with type 2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies, demonstrating that Farxiga significantly reduced HbA1c levels compared to a placebo. The safety profile of Farxiga in this age group was consistent with its profile in adults with type 2 diabetes. This milestone is significant as oral treatment options for pediatric type-2 diabetes have been scarce, highlighting AstraZeneca's dedication to advancing treatments for cardiovascular, renal, and metabolic diseases.

In March 2024, Nirma Limited, an India-based company in the chemical industry specializing in manufacturing, retailing, and distributing commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for $682 million, the amount undisclosed. Through this acquisition, Nirma Limited aims to strengthen its foothold in the pharmaceutical sector, diversify its product portfolio, and leverage research and development capabilities to drive sustainable long-term growth. Glenmark Life Sciences, an India-based pharmaceutical company, manufactures active pharmaceutical ingredients (APIs) for empagliflozin, dapagliflozin, and canagliflozin, which are used in diabetes treatment production.

Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.

North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on empagliflozin, dapagliflozin and canagliflozin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for empagliflozin, dapagliflozin and canagliflozin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The empagliflozin, dapagliflozin and canagliflozin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Empagliflozin, Dapagliflozin And Canagliflozin Market Characteristics

3. Empagliflozin, Dapagliflozin And Canagliflozin Market Trends And Strategies

4. Empagliflozin, Dapagliflozin And Canagliflozin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Empagliflozin, Dapagliflozin And Canagliflozin Growth Analysis And Strategic Analysis Framework

6. Empagliflozin, Dapagliflozin And Canagliflozin Market Segmentation

7. Empagliflozin, Dapagliflozin And Canagliflozin Market Regional And Country Analysis

8. Asia-Pacific Empagliflozin, Dapagliflozin And Canagliflozin Market

9. China Empagliflozin, Dapagliflozin And Canagliflozin Market

10. India Empagliflozin, Dapagliflozin And Canagliflozin Market

11. Japan Empagliflozin, Dapagliflozin And Canagliflozin Market

12. Australia Empagliflozin, Dapagliflozin And Canagliflozin Market

13. Indonesia Empagliflozin, Dapagliflozin And Canagliflozin Market

14. South Korea Empagliflozin, Dapagliflozin And Canagliflozin Market

15. Western Europe Empagliflozin, Dapagliflozin And Canagliflozin Market

16. UK Empagliflozin, Dapagliflozin And Canagliflozin Market

17. Germany Empagliflozin, Dapagliflozin And Canagliflozin Market

18. France Empagliflozin, Dapagliflozin And Canagliflozin Market

19. Italy Empagliflozin, Dapagliflozin And Canagliflozin Market

20. Spain Empagliflozin, Dapagliflozin And Canagliflozin Market

21. Eastern Europe Empagliflozin, Dapagliflozin And Canagliflozin Market

22. Russia Empagliflozin, Dapagliflozin And Canagliflozin Market

23. North America Empagliflozin, Dapagliflozin And Canagliflozin Market

24. USA Empagliflozin, Dapagliflozin And Canagliflozin Market

25. Canada Empagliflozin, Dapagliflozin And Canagliflozin Market

26. South America Empagliflozin, Dapagliflozin And Canagliflozin Market

27. Brazil Empagliflozin, Dapagliflozin And Canagliflozin Market

28. Middle East Empagliflozin, Dapagliflozin And Canagliflozin Market

29. Africa Empagliflozin, Dapagliflozin And Canagliflozin Market

30. Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Landscape And Company Profiles

31. Empagliflozin, Dapagliflozin And Canagliflozin Market Other Major And Innovative Companies

32. Global Empagliflozin, Dapagliflozin And Canagliflozin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Empagliflozin, Dapagliflozin And Canagliflozin Market

34. Recent Developments In The Empagliflozin, Dapagliflozin And Canagliflozin Market

35. Empagliflozin, Dapagliflozin And Canagliflozin Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기